Concert Pharmaceutic (CNCE) 10.42 $CNCE Concert
Post# of 273254
Posted On: 09/21/2016 7:18:24 PM
Concert Pharmaceutic (CNCE) 10.42 $CNCE
Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
BusinessWire - Wed Sep 21, 3:01PM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656 under fasted and fed conditions along with results from the Phase 1 multiple ascending dose study will be presented. Details on the upcoming poster presentation follow below.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Expands Management Team
BusinessWire - Tue Sep 06, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the expansion of its senior management team with the appointment of executives in regulatory affairs and commercial strategy to serve in leadership roles as the Company advances its clinical pipeline. Christine Boisclair has been appointed as Vice President, Regulatory Affairs, with primary responsibility for planning and coordinating Concert's regulatory submissions to the U.S. Food and Drug Administration (FDA) and other regulatory authorities. She replaces Mark Roessel, who recently retired following a long and successful career in the pharmaceutical industry. Scott Weintraub has joined Concert in the newly created position of Vice President, Commercial and Product Strategy, with responsibilities including overseeing the Company's commercial strategy and market assessments for Concert's drug candidates and pipeline.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
BusinessWire - Thu Sep 01, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update
BusinessWire - Tue Aug 09, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 9, 2016
BusinessWire - Tue Aug 02, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss second quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference
BusinessWire - Fri Jun 10, 9:30AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ascending dose trial of CTP-656, a next generation CFTR potentiator being developed for the treatment of cystic fibrosis. The Phase 1 healthy volunteer trial included a single dose tablet crossover comparison with Kalydeco(R), the current standard of care for certain gating mutations of cystic fibrosis, showing that CTP-656 provided substantially superior key exposure parameters. The Phase 1 results support the development of CTP-656 as a once-daily potentiator for the treatment of cystic fibrosis. The results were presented by Concert during an oral presentation at the European Cystic Fibrosis Conference being held in Basel, Switzerland.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata
BusinessWire - Thu May 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for which there are currently no approved treatments. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, which is commercially available under the name Jakafi(R) in the United States for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease. Concert's Phase 1 program will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of single- and multiple-ascending doses of CTP-543 in healthy volunteers.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Present at Several Upcoming Investor Conferences
BusinessWire - Tue May 17, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
CNCE: 10.42 (-0.11)
Concert reports 1Q loss
Automated Insights - Thu May 05, 6:32AM CDT
LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Thursday reported a loss of $13.9 million in its first quarter.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata
BusinessWire - Wed May 04, 3:02PM CDT
--Conference Call Scheduled Tomorrow at 8:30 a.m. EDT for Company Update and First Quarter 2016 Financial Results
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis
BusinessWire - Thu Apr 28, 3:02PM CDT
--Data to be Presented at the European Cystic Fibrosis Conference in June 2016
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Report First Quarter 2016 Financial Results on May 5, 2016
BusinessWire - Thu Apr 28, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals (CNCE) in Focus: Stock Rises 5.6%
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 7:15AM CDT
Concert Pharmaceuticals, Inc. (CNCE) shares rise almost 6% in the last trading session.
CALA: 3.18 (+0.01), CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Names Christine van Heek to Board of Directors
BusinessWire - Thu Apr 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Christine van Heek has been appointed to its Board of Directors and will serve as a member of its audit committee effective April 8, 2016. Ms. van Heek has more than 30 years of experience in the healthcare and biotechnology industry, including 13 years at Genzyme Corporation where she held positions as President of the Therapeutics Division, General Manager of the Renal Division, and Vice President of Global Marketing. Ms. van Heek replaces Helmut M. Schuhsler, Ph.D. who has resigned from Concert's Board of Directors.
CNCE: 10.42 (-0.11)
Global Schistosomiasis Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/k4h9bf/schistosomiasis) has announced the addition of the "Schistosomiasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schistosomiasis Overview - Therapeutics Development - Pipeline Products for Schistosomiasis - Overview - Pipeline Products for Schistosomiasis - Comparative Analysis - Schistosomiasis - Therapeutics under Development by Companies - Schistosomiasis - Therapeutics under Investigation by Universities/Institutes - Schistosomiasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schistosomiasis - Products under Development by Companies - Schistosomiasis - Products under Investigation by Universities/Institutes - Schistosomiasis - Companies Involved in Therapeutics Development - BioDiem Ltd - Concert Pharmaceuticals, Inc. - Kancera AB - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/k4...tosomiasis
CNCE: 10.42 (-0.11)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 14.73 (-0.09), VRTX: 91.82 (+0.13), PFE: 34.28 (+0.47), GSK: 43.21 (+0.15), CNCE: 10.42 (-0.11), GLPG: 67.59 (+0.16), CYCC: 5.88 (-0.10), PTI: 13.42 (+0.34), SHPG: 204.00 (-2.56), PULM: 1.60 (+0.05), MRK: 62.70 (+0.76), NVLS: 8.74 (-0.25), PTCT: 10.44 (+0.23), KMDA: 4.72 (-0.08), AKTX: 8.95 (-0.05), NVS: 81.52 (+0.46)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 14.73 (-0.09), CYCC: 5.88 (-0.10), HZNP: 19.17 (+0.26), KMDA: 4.72 (-0.08), GSK: 43.21 (+0.15), AKTX: 8.95 (-0.05), APHB: 1.51 (-0.03), CNCE: 10.42 (-0.11), GLPG: 67.59 (+0.16)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 34.28 (+0.47), GSK: 43.21 (+0.15), CNCE: 10.42 (-0.11), AZN: 33.75 (+0.10), SHPG: 204.00 (-2.56), CCXI: 5.16 (+0.02), ABBV: 64.10 (+0.82), TBRA: 39.08 (+0.17), XOMA: 0.51 (unch)
Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma
ACCESSWIRE - Wed Dec 23, 7:07AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Compugen Ltd (NASDAQ: CGEN), ChemoCentryx Inc. (NASDAQ: CCXI), and Concert Pharmaceuticals Inc. (NASDAQ: CNCE). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 22, 2015, the NASDAQ Composite ended at 5,001.11, up 0.65%, the Dow Jones Industrial Average advanced 0.96%, to finish the day at 17,417.27, and the S&P 500 closed at 2,038.97, up 0.88%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
CCXI: 5.16 (+0.02), CGEN: 6.70 (+0.04), ARNA: 1.78 (+0.07), CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
BusinessWire - Wed Sep 21, 3:01PM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656 under fasted and fed conditions along with results from the Phase 1 multiple ascending dose study will be presented. Details on the upcoming poster presentation follow below.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Expands Management Team
BusinessWire - Tue Sep 06, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the expansion of its senior management team with the appointment of executives in regulatory affairs and commercial strategy to serve in leadership roles as the Company advances its clinical pipeline. Christine Boisclair has been appointed as Vice President, Regulatory Affairs, with primary responsibility for planning and coordinating Concert's regulatory submissions to the U.S. Food and Drug Administration (FDA) and other regulatory authorities. She replaces Mark Roessel, who recently retired following a long and successful career in the pharmaceutical industry. Scott Weintraub has joined Concert in the newly created position of Vice President, Commercial and Product Strategy, with responsibilities including overseeing the Company's commercial strategy and market assessments for Concert's drug candidates and pipeline.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
BusinessWire - Thu Sep 01, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update
BusinessWire - Tue Aug 09, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 9, 2016
BusinessWire - Tue Aug 02, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss second quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference
BusinessWire - Fri Jun 10, 9:30AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ascending dose trial of CTP-656, a next generation CFTR potentiator being developed for the treatment of cystic fibrosis. The Phase 1 healthy volunteer trial included a single dose tablet crossover comparison with Kalydeco(R), the current standard of care for certain gating mutations of cystic fibrosis, showing that CTP-656 provided substantially superior key exposure parameters. The Phase 1 results support the development of CTP-656 as a once-daily potentiator for the treatment of cystic fibrosis. The results were presented by Concert during an oral presentation at the European Cystic Fibrosis Conference being held in Basel, Switzerland.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata
BusinessWire - Thu May 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for which there are currently no approved treatments. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, which is commercially available under the name Jakafi(R) in the United States for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease. Concert's Phase 1 program will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of single- and multiple-ascending doses of CTP-543 in healthy volunteers.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Present at Several Upcoming Investor Conferences
BusinessWire - Tue May 17, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
CNCE: 10.42 (-0.11)
Concert reports 1Q loss
Automated Insights - Thu May 05, 6:32AM CDT
LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Thursday reported a loss of $13.9 million in its first quarter.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016.
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata
BusinessWire - Wed May 04, 3:02PM CDT
--Conference Call Scheduled Tomorrow at 8:30 a.m. EDT for Company Update and First Quarter 2016 Financial Results
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis
BusinessWire - Thu Apr 28, 3:02PM CDT
--Data to be Presented at the European Cystic Fibrosis Conference in June 2016
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals to Report First Quarter 2016 Financial Results on May 5, 2016
BusinessWire - Thu Apr 28, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 10.42 (-0.11)
Concert Pharmaceuticals (CNCE) in Focus: Stock Rises 5.6%
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 7:15AM CDT
Concert Pharmaceuticals, Inc. (CNCE) shares rise almost 6% in the last trading session.
CALA: 3.18 (+0.01), CNCE: 10.42 (-0.11)
Concert Pharmaceuticals Names Christine van Heek to Board of Directors
BusinessWire - Thu Apr 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Christine van Heek has been appointed to its Board of Directors and will serve as a member of its audit committee effective April 8, 2016. Ms. van Heek has more than 30 years of experience in the healthcare and biotechnology industry, including 13 years at Genzyme Corporation where she held positions as President of the Therapeutics Division, General Manager of the Renal Division, and Vice President of Global Marketing. Ms. van Heek replaces Helmut M. Schuhsler, Ph.D. who has resigned from Concert's Board of Directors.
CNCE: 10.42 (-0.11)
Global Schistosomiasis Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/k4h9bf/schistosomiasis) has announced the addition of the "Schistosomiasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schistosomiasis Overview - Therapeutics Development - Pipeline Products for Schistosomiasis - Overview - Pipeline Products for Schistosomiasis - Comparative Analysis - Schistosomiasis - Therapeutics under Development by Companies - Schistosomiasis - Therapeutics under Investigation by Universities/Institutes - Schistosomiasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schistosomiasis - Products under Development by Companies - Schistosomiasis - Products under Investigation by Universities/Institutes - Schistosomiasis - Companies Involved in Therapeutics Development - BioDiem Ltd - Concert Pharmaceuticals, Inc. - Kancera AB - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/k4...tosomiasis
CNCE: 10.42 (-0.11)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 14.73 (-0.09), VRTX: 91.82 (+0.13), PFE: 34.28 (+0.47), GSK: 43.21 (+0.15), CNCE: 10.42 (-0.11), GLPG: 67.59 (+0.16), CYCC: 5.88 (-0.10), PTI: 13.42 (+0.34), SHPG: 204.00 (-2.56), PULM: 1.60 (+0.05), MRK: 62.70 (+0.76), NVLS: 8.74 (-0.25), PTCT: 10.44 (+0.23), KMDA: 4.72 (-0.08), AKTX: 8.95 (-0.05), NVS: 81.52 (+0.46)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 14.73 (-0.09), CYCC: 5.88 (-0.10), HZNP: 19.17 (+0.26), KMDA: 4.72 (-0.08), GSK: 43.21 (+0.15), AKTX: 8.95 (-0.05), APHB: 1.51 (-0.03), CNCE: 10.42 (-0.11), GLPG: 67.59 (+0.16)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 34.28 (+0.47), GSK: 43.21 (+0.15), CNCE: 10.42 (-0.11), AZN: 33.75 (+0.10), SHPG: 204.00 (-2.56), CCXI: 5.16 (+0.02), ABBV: 64.10 (+0.82), TBRA: 39.08 (+0.17), XOMA: 0.51 (unch)
Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma
ACCESSWIRE - Wed Dec 23, 7:07AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Compugen Ltd (NASDAQ: CGEN), ChemoCentryx Inc. (NASDAQ: CCXI), and Concert Pharmaceuticals Inc. (NASDAQ: CNCE). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 22, 2015, the NASDAQ Composite ended at 5,001.11, up 0.65%, the Dow Jones Industrial Average advanced 0.96%, to finish the day at 17,417.27, and the S&P 500 closed at 2,038.97, up 0.88%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
CCXI: 5.16 (+0.02), CGEN: 6.70 (+0.04), ARNA: 1.78 (+0.07), CNCE: 10.42 (-0.11)
(0)
(0)Scroll down for more posts ▼